All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1200+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Business Development

Hutchmed lands $20M milestone payment from AstraZeneca after Fruzaqla hits $200M in sales
Small molecule, colorectal cancer - Read more

Mochida Pharmaceutical acquires Japan rights to Tyvaso DPI from United Therapeutics
Small molecule, pulmonary arterial hypertension, interstitial lung disease - Read more

SPC Korea nabs South Korea licensing and distribution rights to Lipocine’s Tlando
Small molecule, testosterone replacement therapy - Read more

TME Pharma nabs €2.4M ($2.6M) German Federal Grant for planned Ph2 for NOX-A12
RNA oligonucleotide, glioblastoma, cancer - Read more

THE GOOD
Clinical Trials

Ventus Therapeutics’ VENT-03 succeeds in Ph1, gears up for Ph2 targeting systemic lupus erythematosus
Small molecule, systemic lupus erythematosus - Read more

Recce Pharmaceuticals touts nods from independent safety board regarding interim Ph2 data for R327G
Small molecule, skin infections, diabetic foot infections - Read more

Anavex Life Sciences’ Alzheimer’s hopeful blarcamesine hits “pre-specified efficacay” in Ph2b/3 trial
Small molecule, Alzheimer’s - Read more

Sinaptica Therapeutics showcases promising Alzheimer’s-related cognitive decline-slowing Ph2 data utilizing non-invasive transcranial magnetic brain stimulation
Transcranial magnetic brain stimulation - Read more

THE GOOD
Earnings & Finances

Bristol Myers Squibb reports a smashing Q3
Big pharma earnings - Read more

argenx posts continues growth in Q3, though some concerns linger
Antibody fragment, generalized myasthenia gravis - Read more

Amgen’s $27.8B buyout of Horizon Therapeutics and its commercial assets continue delivering the goods, as Q3’s $8.5B revenue is 23% more than Q3 2023
Big pharma earnings, monoclonal antibody, thyroid eye disease - Read more

Galapagos posts “solid” Q3 progress, including advancing CAR-T programs through the clinic
Cell therapy, non-Hodgkin lymphoma, cancer - Read more

Madrigal Pharmaceuticals’ Rezdiffra sales in Q3 a sMASHing success
Small molecule, metabolic dysfunction-associated steatohepatitis - Read more

PRESENTED BY YOU?
Get the attention of 1200+ Biotech & Pharma Professionals 🤩

Looking to promote your biotech/pharma/life science-focused product or service to a captivated audience of industry professionals?

Consider sponsoring TLDR Biotech - your sponsored feature would go right here!

If you want to see our prospectus or if you’re ready to work with us, just reply to this email or message me on LinkedIn.

⬇️ More Good News ⬇️

THE GOOD
Fundraises

Elektrofi oversubscribed $122.5M Series C, building out commercial-scale GMP facility
Drug development, manufacturing facility - Read more

Evommune $115M Series C, Phase 2 small molecule assets targeting hives
Small molecule, chronic skin hives, urticaria, eczema - Read more

1910 Genetics undisclosed investment from Accenture, collaborate to accelerate drug discovery
Drug discovery, AI, laboratory automation - Read more

Mission BioCapital announces first slate of life science start-up investments, supported by the Platinum Program
Venture capital, biotech investing, life science investing - Read more

THE GOOD
Lawsuits

Avadel Pharmaceuticals notches win against Jazz Pharmaceuticals, as US District Court Judge sides with FDA on granting Lumryz approval (Avadel’s competitor to Jazz’s Xywav)
Small molecule, cataplexy, excessive daytime sleepiness - Read more [Paywall]

THE GOOD
Mergers & Acquisitions

Jade Biosciences reverse merges with Aerovate Therapeutics
Monoclonal antibody, IgA nephropathy, kidney disease - Read more

THE GOOD
Partnerships

AbbVie, EvolveImmune Therapeutics novel antibody-based drug discovery partnership leveraging latter’s T-cell engager platform
Antibody, cancer, T-cell engager, drug discovery - Read more

Gilead Sciences, AbTherx expand collab involving “innovative” antibody discovery tech
Antibody, drug discovery - Read more

Absci, Twist Bioscience collab on AI-driven novel antibody design
Antibody, drug design, AI - Read more

THE GOOD
Politics & Policy

UK government unveils Life Sciences Innovative Manufacturing Fund, £520M ($675M) in capital grants for biopharma, med tech manufacturing infrastructure
Public funding, biopharma manufacturing - Read more

THE GOOD
Strategic Plans

Wave Life Sciences makes obesity and cardiometabolic waves during virtual Research Day
siRNA, obesity, RNA editing, cardiometabolic disorders - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Approvals & Labels

Lexicon Pharmaceuticals’ gets an 11-to-3 thumbs down from FDA adcom for Zynquista in Type 1 diabetes
Small molecule, type 1 diabetes - Read more

THE BAD
Business Development

Equillium stock craters after Ono Pharmaceutical’s option to acquire itolizumab rights expires
Monoclonal antibody, graft-versus-host disease, lupus nephritis - Read more

THE BAD
Clinical Trials

Corcept Therapeutics’ relacorilant misses Ph3 endpoint in Cushing’s syndrome trial
Small molecule, Cushing’s syndrome - Read more

Takeda ceases Ph2 danavorexton trial after slow enrolment in target patient population
Small molecule, post-surgical post-anesthesia sleep apnea-related respiratory complications - Read more 

UCB’s Alzheimer’s hopeful bepranemab misses primary endpoint in Ph2a (though some optimism remains as secondary goals met)
Monoclonal antibody, Alzheimer’s disease - Read more

THE BAD
Earnings & Finances

Merck posts disappointing Q3 earnings, driven by slowing Gardasil, Januvia revenue
Vaccine, human papillomavirus, small molecule, type 2 diabetes - Read more

THE BAD
Layoffs

Matinas BioPharma hits the brakes and cuts 80% of workforce after partnership negotiations for lead asset MAT2203 fell through
Small molecule, antifungal - Read more

Compass Pathways delays clinical readouts and lays off 30% of workforce
Small molecule, depression, psychedelic - Read more

THE BAD
Strategic Plans

Boehringer Ingelheim halts BI 1820237 obesity hopeful development, part of Gubra partnership
Small molecule, obesity - Read more

Baxter leave China IV fluids market, citing local competition and ongoing US shortages
IV fluids - Read more

Alnylam suspends clinical development of type 2 diabetes RNAi asset ALN-KHK
RNAi, type 2 diabetes - Read more

Amgen discontinues development of fipaxalparant after missing 14 endpoints in Ph2 idiopathic pulmonary fibrosis trial
Small molecule, idiopathic pulmonary fibrosis - Read more

THE UGLY
Criminal Acts

Teva Pharmaceuticals slapped with whopping €463M ($502M) fine by European Commission for anti-competitive practices related to MS med Copaxone
Small molecule, multiple sclerosis - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here